Bruker Daltonics Introduces Novel Autoflex TOF/TOF System.

Business Editors/High-Tech Writers

EDINBURGH, Scotland, U.K.--(BUSINESS WIRE)--Sept. 1, 2003

International Mass Spectrometry Conference (IMSC)

New High-Performance AutoFlex(TM) TOF/TOF is Affordable, Offers

Small Footprint; T3-Sequencing(TM) for Top-Down Proteomics Introduced

for UltraFlex TOF/TOF

Bruker Daltonics Inc., a subsidiary of Bruker BioSciences Corporation (NASDAQ: BRKR), today introduces the autoflex(TM) TOF/TOF system, a compact high-performance MALDI-TOF/TOF mass spectrometer. This first vertical TOF/TOF system, which offers many of the high-performance MS/MS characteristics of larger TOF/TOF systems, requires less lab space, and is priced attractively at $375,000.

Since the introduction of Bruker Daltonics' ultraflex(TM) TOF/TOF system two years ago, MALDI-TOF/TOF technology has been adopted very rapidly by the global proteomics community. Advantages of MALDI-TOF/TOF technology include superb MS/MS sensitivity, sequence coverage and information content due to the inherent high-energy MS/MS fragment generation. At the same time, TOF/TOF tandem mass spectra can be acquired with unprecedented throughput and ease of use, and the results are straight-forward to interpret automatically.

The new autoflex TOF/TOF, for the first time, provides the power of MALDI-TOF/TOF in a compact and affordable research system for proteomics applications. The system enables extremely fast, automated protein identification by MALDI-TOF peptide mass fingerprinting, immediately followed by more detailed protein structural characterization using MALDI-TOF/TOF tandem mass spectrometry. The vertical autoflex TOF/TOF can be seamlessly integrated into any protein research or biomarker discovery laboratory.

The autoflex TOF/TOF benefits from Bruker Daltonics' MALDI sample targets which use the industry-standard microtitre plate (MTP) format, and are thus easily compatible with many standard microbiology or clinical diagnostics sample preparation robots. An optional robotic arm is available for automated delivery of additional MTP MALDI targets into the autoflex TOF/TOF for unattended 24/7 operation.

The autoflex TOF/TOF incorporates Bruker Daltonics' patented AnchorChip(TM) technology, which provides homogeneous, exactly-positioned samples on the MALDI-target for robust and fast automation, as well as a sensitivity boost by up to two orders of magnitude. The autoflex TOF/TOF can be an integral module of either Bruker Daltonics' Proteineer(TM) solution for high-success expression proteomics, or the ClinProt(TM) solution for biomarker discovery and clinical proteomics.

The Bruker Daltonics ultraflex TOF/TOF has already been very successfully used for de novo peptide sequencing. At IMSC, Bruker Daltonics now also announces that its top-of-the-line UltraFlex TOF/TOF is further enhanced to offer T3-Sequencing(TM), a novel and unique "top-down proteomics" method for obtaining extensive structural information on intact, undigested proteins. Moreover, UltraFlex TOF/TOF mass accuracy has been dramatically improved and is now specified at 5 ppm for peptides, which is very beneficial for both peptide mass fingerprinting and de novo peptide sequencing.

"Our MALDI-TOF/TOF systems quickly have become very accepted in proteomics research due to the significant jump in MS/MS performance and information content afforded by this exciting technology," commented Frank H. Laukien, Ph.D., President and CEO of Bruker Daltonics. "With the introduction of the autoflex TOF/TOF, we are now offering high-energy MALDI-TOF/TOF capabilities to many more protein research laboratories who wish to go far beyond older MALDI-TOF PSD or MALDI-Q-q-TOF technologies."

"We are also excited to extend the performance leadership of our top-of-the-line ultraflex TOF/TOF by introducing the unique and very useful T3-Sequencing top-down proteomics method, while at the same time dramatically improving mass accuracy. We believe this makes our ultraFlex TOF/TOF the only true protein and peptide analyzer."

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2002, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.